US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEUROGENE INC

16.97

+1.5710.19%

Post-market: 16.970.00000.00%19:04 EDT

Volume:199.98K

Turnover:3.37M

Market Cap:242.03M

PE:-3.96

High:17.45

Open:15.54

Low:15.54

Close:15.40

Loading ...

Overview Company News Filings

Neurogene price target raised to $72 from $54 at Baird

Neurogene price target raised to $55 from $49 at H.C. Wainwright

William Blair Sticks to Its Buy Rating for Neurogene (NGNE)

Neurogene Inc : Leerink Partners Raises Target Price to $72 From $45

THOMSON REUTERS

BRIEF-Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants In Ngn-401 Gene Therapy Clinical Trial For Rett Syndrome

Neurogene plummets 35% on gene therapy trial data for Rett syndrome

Neurogene Not Moving Forward With Batten Disease Treatment Program -- Shares Fall After Hours

MT Newswires Live

BUZZ-Neurogene not to proceed with gene therapy for Batten disease; shares drop

Neurogene Inc Shares Down 27.3% at $52 After the Bell Following Update on Clinical Trial

THOMSON REUTERS

Neurogene reports ‘positive’ interim efficacy data from NGN-401 participants

Neurogene Inc - Participants Show 28-52% Improvement in Rett Syndrome Behavior Questionnaire

THOMSON REUTERS

Neurogene Inc - Gains FDA Alignment on Potency Assay Strategy for Ngn-401

THOMSON REUTERS

Neurogene Inc - to Halt Ngn-101 Cln5 Batten Disease Gene Therapy Program

THOMSON REUTERS

Neurogene Inc: Plans to Provide an Update of Registrational Trial Design in H1 2025

THOMSON REUTERS

Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants in Ngn-401 Gene Therapy Clinical Trial for Rett Syndrome

THOMSON REUTERS

Neurogene Inc - Low-Dose Ngn-401 Well-Tolerated With Favorable Safety Profile

THOMSON REUTERS

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Neurogene Reaches 52-Week High on $200M Private Placement

Neurogene Up Nearly 45%, on Pace for Largest Percent Increase Since December 2019 -- Data Talk

BRIEF-Neurogene Announces Oversubscribed $200 Mln Private Placement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NGNE/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NGNE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGNE\",,,,,undefined,":{"symbol":"NGNE","market":"US","secType":"STK","nameCN":"NEUROGENE INC","latestPrice":16.97,"timestamp":1746216000000,"preClose":15.4,"halted":0,"volume":199976,"hourTrading":{"tag":"盘后","latestPrice":16.97,"preClose":16.97,"latestTime":"19:04 EDT","volume":822,"amount":13988.08,"timestamp":1746227080641},"delay":0,"floatShares":4877966,"shares":14262066,"eps":-4.28,"marketStatus":"Market Closed","change":1.57,"latestTime":"05-02 16:00:00 EDT","open":15.54,"high":17.45,"low":15.54,"amount":3372693.628192,"amplitude":0.124026,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.28,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":7,"adr":0,"listingDate":1394168400000,"exchange":"NASDAQ","adjPreClose":15.4,"preHourTrading":{"tag":"盘前","latestPrice":14.81,"preClose":15.4,"latestTime":"09:13 EDT","volume":13,"amount":196.720004,"timestamp":1746191596428},"postHourTrading":{"tag":"盘后","latestPrice":16.97,"preClose":16.97,"latestTime":"19:04 EDT","volume":822,"amount":13988.08,"timestamp":1746227080641},"volumeRatio":0.9567570463586836,"impliedVol":0.981,"impliedVolPercentile":0.4333},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGNE\",,,,,undefined,":{"symbol":"NGNE","floatShares":4877966,"roa":"-18.49%","roe":"-30.28%","lyrEps":-4.277545,"volumeRatio":0.9567570463586836,"shares":14262066,"dividePrice":0,"high":17.45,"amplitude":0.124026,"preClose":15.4,"low":15.54,"week52Low":6.875,"pbRate":"0.78","psRate":"261.65","week52High":74.49,"institutionHeld":0,"latestPrice":16.97,"eps":-4.28,"divideRate":0,"volume":199976,"delay":0,"ttmEps":-4.28,"open":15.54,"prevYearClose":22.86,"prevWeekClose":15.41,"prevMonthClose":15,"prevQuarterClose":11.71,"fiveDayClose":15.41,"twentyDayClose":9.67,"sixtyDayClose":21.53},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NGNE\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2482708570","title":"Neurogene price target raised to $72 from $54 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2482708570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482708570?lang=en_us&edition=fundamental","pubTime":"2024-11-12 19:50","pubTimestamp":1731412207,"startTime":"0","endTime":"0","summary":"Baird analyst Joel Beatty raised the firm’s price target on Neurogene (NGNE) to $72 from $54 and keeps an Outperform rating on the shares. The firm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurogene-price-target-raised-to-72-from-54-at-baird?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurogene-price-target-raised-to-72-from-54-at-baird?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2482772924","title":"Neurogene price target raised to $55 from $49 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2482772924","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482772924?lang=en_us&edition=fundamental","pubTime":"2024-11-12 19:15","pubTimestamp":1731410112,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Neurogene (NGNE) to $55 from $49 and keeps a Buy rating on the shares. The firm says the low-dose...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurogene-price-target-raised-to-55-from-49-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurogene-price-target-raised-to-55-from-49-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2482826771","title":"William Blair Sticks to Its Buy Rating for Neurogene (NGNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482826771","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482826771?lang=en_us&edition=fundamental","pubTime":"2024-11-12 18:35","pubTimestamp":1731407745,"startTime":"0","endTime":"0","summary":"In a report released today, Sami Corwin from William Blair maintained a Buy rating on Neurogene (NGNE – Research Report). The company’s shares clos...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-sticks-to-its-buy-rating-for-neurogene-ngne?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-sticks-to-its-buy-rating-for-neurogene-ngne?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE"],"gpt_icon":0},{"id":"2482745800","title":"Neurogene Inc :  Leerink Partners Raises Target Price to $72 From $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2482745800","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482745800?lang=en_us&edition=fundamental","pubTime":"2024-11-12 13:22","pubTimestamp":1731388937,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nFWN3MJ031:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2482769182","title":"BRIEF-Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants In Ngn-401 Gene Therapy Clinical Trial For Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2482769182","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482769182?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:46","pubTimestamp":1731361587,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants In Ngn-401 Gene Therapy Clinical Trial For Rett SyndromeNov 11 (Reuters) - Neurogene Inc NGNE.O:N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAZFJPX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2482793734","title":"Neurogene plummets 35% on gene therapy trial data for Rett syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2482793734","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482793734?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:42","pubTimestamp":1731361329,"startTime":"0","endTime":"0","summary":"designer491/iStock via Getty ImagesNeurogene (NASDAQ:NGNE) has fallen ~35% in after-hours trading Monday after reporting interim phase 1/2 data on pediatrics patients given NGN-401, a gene therapy for the treatment of Rett syndrome. The company is examining the candidate in both low and high","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/488884858/image_488884858.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/488884858/image_488884858.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4276690-neurogene-plummets-35-gene-therapy-trial-data-rett-syndrome","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["NQmain","QLD","BK4139",".IXIC","PSQ","QID","SQQQ","TSHA","MNQmain","NGNE","TQQQ"],"gpt_icon":0},{"id":"2482766096","title":"Neurogene Not Moving Forward With Batten Disease Treatment Program -- Shares Fall After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2482766096","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482766096?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:37","pubTimestamp":1731361022,"startTime":"0","endTime":"0","summary":"Neurogene (NGNE) said Monday it likely will not move forward with its NGN-101 CLN5 Batten disease gene therapy program after the US Food and Drug Administration denied a Regenerative Medicine Advance ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4202","FORD","BK4139","NGNE"],"gpt_icon":0},{"id":"2482148766","title":"BUZZ-Neurogene not to proceed with gene therapy for Batten disease; shares drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2482148766","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482148766?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:31","pubTimestamp":1731360669,"startTime":"0","endTime":"0","summary":"** Shares of therapy developer Neurogene    fall 46.9% to $37.99 aftermarket   ** Co says it does not expect to move forward with the development of its gene therapy for Batten disease    ** Says the decision was made after the FDA denied co's Regenerative Medicine Advance Therapy  application to the FDA for the gene therapy    ** A therapy is eligible for RMAT designation if it is used for treating a serious or life-threatening disease or condition and if preliminary clinical evidence shows the therapy has potential to address unmet medical needs   ** Co says it is currently evaluating options for the developmental program   ** Batten disease is a rare, inherited, and fatal disorder that affects the nervous system   ** Up to last close, stock up more than double YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2482658627","title":"Neurogene Inc Shares Down 27.3% at $52 After the Bell Following Update on Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482658627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482658627?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:07","pubTimestamp":1731359244,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nL1N3MI0YA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2482765524","title":"Neurogene reports ‘positive’ interim efficacy data from NGN-401 participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2482765524","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482765524?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:05","pubTimestamp":1731359129,"startTime":"0","endTime":"0","summary":"Neurogene (NGNE) announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurogene-reports-positive-interim-efficacy-data-from-ngn-401-participants?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurogene-reports-positive-interim-efficacy-data-from-ngn-401-participants?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2482776344","title":"Neurogene Inc - Participants Show 28-52% Improvement in Rett Syndrome Behavior Questionnaire","url":"https://stock-news.laohu8.com/highlight/detail?id=2482776344","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482776344?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:01","pubTimestamp":1731358860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAZFJPX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2482763473","title":"Neurogene Inc - Gains FDA Alignment on Potency Assay Strategy for Ngn-401","url":"https://stock-news.laohu8.com/highlight/detail?id=2482763473","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482763473?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:01","pubTimestamp":1731358860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAZFJPX:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2482763421","title":"Neurogene Inc - to Halt Ngn-101 Cln5 Batten Disease Gene Therapy Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2482763421","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482763421?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:01","pubTimestamp":1731358860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAZFJPX:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2482476347","title":"Neurogene Inc: Plans to Provide an Update of Registrational Trial Design in H1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2482476347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482476347?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:01","pubTimestamp":1731358860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAZFJPX:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2482476310","title":"Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants in Ngn-401 Gene Therapy Clinical Trial for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2482476310","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482476310?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:01","pubTimestamp":1731358860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAZFJPX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2482376342","title":"Neurogene Inc - Low-Dose Ngn-401 Well-Tolerated With Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2482376342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482376342?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:01","pubTimestamp":1731358860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAZFJPX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2482763040","title":"Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2482763040","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482763040?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:01","pubTimestamp":1731358860,"startTime":"0","endTime":"0","summary":"All participants experienced a 2-point improvement in the clinician-rated Clinical Global Impression-Improvement  scale from baseline. All participants improved in the caregiver-completed Rett Syndrome Behavior Questionnaire , ranging from 28 to 52 percent improvement from baseline. All participants with disruptions in sleep, constipation, and dysphagia at baseline demonstrated objective improvements. Gains in skill and developmental milestones were consistent, durable, deepened over time and demonstrated improvements not expected based on natural history data. Company to host investor/analyst webcast today, November 11, 2024, at 4:30 p.m. ET. NEW YORK, November 11, 2024----Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial designed to evalua","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/138KeOX7dIdsyxddlQ8k8Q--~B/aD00ODA7dz0zNzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a5dc4f0685f5aca38ffa36e3d0d86dc8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/138KeOX7dIdsyxddlQ8k8Q--~B/aD00ODA7dz0zNzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a5dc4f0685f5aca38ffa36e3d0d86dc8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurogene-reports-positive-interim-efficacy-210100415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4528","NGNE","BK4233","UK","BK4205","BK4139"],"gpt_icon":0},{"id":"2481530830","title":"Neurogene Reaches 52-Week High on $200M Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2481530830","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481530830?lang=en_us&edition=fundamental","pubTime":"2024-11-05 02:31","pubTimestamp":1730745060,"startTime":"0","endTime":"0","summary":"Neurogene shares reached a 52-week high after the genetic medicine company announced an oversubscribed private placement of about $200 million.The stock was up 44% to $66.55 on Monday, with an intraday high of $73.59. Shares are up about 243% this year.The company expects the proceeds, combined with existing cash and cash equivalents, will provide runway into the second half of 2027. In August, the company said it expected current cash, cash equivalents and marketable securities to fund operations into the second half of 2026.Participants in the financing include RTW Investments, Casdin Capital, EcoR1 Capital, Redmile Group, Great Point Partners, Commodore Capital and Samsara BioCapital.Neurogene it will host a Nov. 11 webcast to present interim data from its Phase 1/2 trial of NGN-401 for Rett syndrome.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2481981532","title":"Neurogene Up Nearly 45%, on Pace for Largest Percent Increase Since December 2019 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2481981532","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481981532?lang=en_us&edition=fundamental","pubTime":"2024-11-05 01:58","pubTimestamp":1730743080,"startTime":"0","endTime":"0","summary":"Neurogene Inc.  is currently at $66.72, up $20.65 or 44.82%. --Would be highest close since Feb. 2, 2022, when it closed at $67.40. --On pace for largest percent increase since Dec. 9, 2019, when it rose 54.68%. --Currently up three consecutive days; up 52.53% over this period. --Up 244.26% year-to-date; on pace for best year since 2019, when it rose 470.37%. --Down 84.93% from its all-time closing high of $442.60 on Aug. 14, 2015. --Up 387.7% from 52 weeks ago , when it closed at $13.68. --Up 414.8% from its 52-week closing low of $12.96 on Nov. 21, 2023. --Traded as high as $73.59; highest intraday level since Feb. 2, 2022, when it hit $75.00. --Up 59.74% at today's intraday high; largest intraday percent increase since Dec. 24, 2020, when it rose as much as 66.67%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2480588193","title":"BRIEF-Neurogene Announces Oversubscribed $200 Mln Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2480588193","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480588193?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:27","pubTimestamp":1730726858,"startTime":"0","endTime":"0","summary":"Nov 4 (Reuters) - Neurogene Inc   :   * NEUROGENE ANNOUNCES OVERSUBSCRIBED $200 MILLION PRIVATE PLACEMENT   * NEUROGENE INC - PROCEEDS EXPECTED TO FUND COMPANY INTO SECOND HALF OF 2027Source text:    Further company coverage:    (Reuters.Briefs@thomsonreuters.com)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":83,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NGNE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-24","symbol":"NGNE","fiscalQuarterEnding":"2024/12","expectedEps":-1.04,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-0.99},{"market":"US","date":"2024-11-18","symbol":"NGNE","fiscalQuarterEnding":"2024/09","expectedEps":-1.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731906000000,"reportTimeType":"post","actualEps":-1.19},{"market":"US","date":"2024-08-09","symbol":"NGNE","fiscalQuarterEnding":"2024/06","expectedEps":-1.02,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"pre","actualEps":-1.09},{"market":"US","date":"2024-05-10","symbol":"NGNE","fiscalQuarterEnding":"2024/03","expectedEps":-1.03,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"pre","actualEps":1},{"market":"US","date":"2024-03-18","symbol":"NGNE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1710734400000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NGNE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NGNE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5714,"buy":0.4286,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5714,"analysts":7,"updateTime":1719460800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NGNE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NGNE","date":"2025-05-02","current":-2.922866,"percent":0.927673,"low":-19.523035,"twenty":-11.956745,"median":-9.074937,"eighty":-4.83359,"high":-1.458307,"avg":-8.759663,"sd":3.949869,"marketCap":219635816},"quantilePoints":[{"date":"2023-12-29","current":-4.323556,"twenty":-4.185645,"median":-3.978778,"eighty":-3.916869,"marketCap":220311097},{"date":"2024-01-05","current":-5.423319,"twenty":-5.000527,"median":-4.624292,"eighty":-3.978778,"marketCap":276350648},{"date":"2024-01-12","current":-8.005373,"twenty":-7.157271,"median":-5.423319,"eighty":-4.323556,"marketCap":407921769},{"date":"2024-01-19","current":-7.59768,"twenty":-7.599292,"median":-7.086806,"eighty":-4.804734,"marketCap":387147382},{"date":"2024-01-26","current":-8.053188,"twenty":-7.611677,"median":-7.561189,"eighty":-4.985427,"marketCap":410358272},{"date":"2024-02-02","current":-7.741127,"twenty":-7.937424,"median":-7.577547,"eighty":-5.338761,"marketCap":394456888},{"date":"2024-02-09","current":-7.497015,"twenty":-7.980207,"median":-7.59013,"eighty":-6.388695,"marketCap":382017903},{"date":"2024-02-16","current":-7.549864,"twenty":-7.937424,"median":-7.577547,"eighty":-6.995453,"marketCap":384710880},{"date":"2024-02-23","current":-7.622846,"twenty":-7.894138,"median":-7.57503,"eighty":-7.129085,"marketCap":388429751},{"date":"2024-03-01","current":-7.819143,"twenty":-7.894138,"median":-7.588872,"eighty":-7.262969,"marketCap":398432234},{"date":"2024-03-08","current":-9.734292,"twenty":-8.024499,"median":-7.59768,"eighty":-7.381754,"marketCap":496020561},{"date":"2024-03-15","current":-8.697444,"twenty":-8.083388,"median":-7.629138,"eighty":-7.463796,"marketCap":443186933},{"date":"2024-03-22","current":-17.419498,"twenty":-9.10262,"median":-7.660596,"eighty":-7.498525,"marketCap":632623921},{"date":"2024-03-28","current":-17.433655,"twenty":-9.373408,"median":-7.741127,"eighty":-7.499532,"marketCap":633138041},{"date":"2024-04-05","current":-15.090764,"twenty":-9.721205,"median":-7.845567,"eighty":-7.510605,"marketCap":548051280},{"date":"2024-04-12","current":-13.565408,"twenty":-14.180505,"median":-7.97769,"eighty":-7.536275,"marketCap":492654915},{"date":"2024-04-19","current":-11.176509,"twenty":-13.912948,"median":-8.029281,"eighty":-7.549864,"marketCap":405897266},{"date":"2024-04-26","current":-10.571321,"twenty":-13.650346,"median":-8.053188,"eighty":-7.549864,"marketCap":383918661},{"date":"2024-05-03","current":-12.537284,"twenty":-13.442874,"median":-8.146303,"eighty":-7.558924,"marketCap":455316556},{"date":"2024-05-10","current":-11.764996,"twenty":-13.2542,"median":-9.074937,"eighty":-7.57352,"marketCap":427269365},{"date":"2024-05-17","current":-10.587696,"twenty":-13.13876,"median":-9.272492,"eighty":-7.576037,"marketCap":433830864},{"date":"2024-05-24","current":-9.887502,"twenty":-12.800854,"median":-9.44488,"eighty":-7.581574,"marketCap":405140389},{"date":"2024-05-31","current":-10.685033,"twenty":-12.52136,"median":-9.620612,"eighty":-7.588117,"marketCap":437819226},{"date":"2024-06-07","current":-11.771752,"twenty":-12.409114,"median":-9.810897,"eighty":-7.59013,"marketCap":482347539},{"date":"2024-06-14","current":-13.301826,"twenty":-12.457666,"median":-9.93146,"eighty":-7.59013,"marketCap":545042335},{"date":"2024-06-21","current":-9.842528,"twenty":-12.564112,"median":-9.93146,"eighty":-7.59617,"marketCap":403297579},{"date":"2024-06-28","current":-11.030474,"twenty":-12.52136,"median":-10.019377,"eighty":-7.599292,"marketCap":451973662},{"date":"2024-07-05","current":-11.397945,"twenty":-12.537284,"median":-10.188931,"eighty":-7.605739,"marketCap":467030798},{"date":"2024-07-12","current":-13.232134,"twenty":-12.537284,"median":-10.458961,"eighty":-7.622846,"marketCap":542186671},{"date":"2024-07-15","current":-13.48873,"twenty":-12.644595,"median":-10.463671,"eighty":-7.625363,"marketCap":552700705},{"date":"2024-08-02","current":-12.832984,"twenty":-12.76836,"median":-10.468381,"eighty":-7.627879,"marketCap":525831507},{"date":"2024-08-09","current":-11.578513,"twenty":-12.617767,"median":-10.579508,"eighty":-7.644992,"marketCap":474429562},{"date":"2024-08-16","current":-9.721942,"twenty":-12.533918,"median":-10.468381,"eighty":-7.659841,"marketCap":462832495},{"date":"2024-08-23","current":-9.22793,"twenty":-12.500388,"median":-10.20777,"eighty":-7.686769,"marketCap":439314055},{"date":"2024-08-30","current":-9.934831,"twenty":-12.3607,"median":-10.082175,"eighty":-7.732068,"marketCap":472967513},{"date":"2024-09-06","current":-9.383503,"twenty":-12.215183,"median":-10.030358,"eighty":-7.751697,"marketCap":446720414},{"date":"2024-09-13","current":-11.015654,"twenty":-12.198503,"median":-10.056266,"eighty":-7.799009,"marketCap":524422220},{"date":"2024-09-20","current":-11.343175,"twenty":-12.111032,"median":-10.20463,"eighty":-7.829713,"marketCap":540014556},{"date":"2024-09-27","current":-10.69359,"twenty":-12.018852,"median":-10.282823,"eighty":-7.883065,"marketCap":509089757},{"date":"2024-10-04","current":-12.12104,"twenty":-12.018852,"median":-10.468381,"eighty":-7.937424,"marketCap":577046353},{"date":"2024-10-11","current":-13.141817,"twenty":-12.215183,"median":-10.579508,"eighty":-7.980207,"marketCap":625642465},{"date":"2024-10-18","current":-14.443716,"twenty":-12.644595,"median":-10.678753,"eighty":-7.993293,"marketCap":687621999},{"date":"2024-10-25","current":-13.155463,"twenty":-12.975228,"median":-10.69616,"eighty":-8.014936,"marketCap":626292146},{"date":"2024-10-31","current":-11.938174,"twenty":-12.976568,"median":-10.764003,"eighty":-8.053188,"marketCap":568340632},{"date":"2024-11-08","current":-18.968977,"twenty":-13.201862,"median":-10.833215,"eighty":-8.053188,"marketCap":903056103},{"date":"2024-11-15","current":-10.699049,"twenty":-13.232134,"median":-10.867118,"eighty":-8.053188,"marketCap":509349629},{"date":"2024-11-22","current":-3.804354,"twenty":-13.201862,"median":-10.811892,"eighty":-8.005373,"marketCap":202570426},{"date":"2024-11-29","current":-7.081932,"twenty":-13.164743,"median":-10.73726,"eighty":-7.916284,"marketCap":377091628},{"date":"2024-12-06","current":-6.123936,"twenty":-13.144546,"median":-10.69616,"eighty":-7.738107,"marketCap":326081199},{"date":"2024-12-13","current":-6.220014,"twenty":-13.009618,"median":-10.678753,"eighty":-7.632912,"marketCap":331197071},{"date":"2024-12-20","current":-6.147607,"twenty":-12.971208,"median":-10.579508,"eighty":-7.59013,"marketCap":327341631},{"date":"2024-12-27","current":-6.711544,"twenty":-12.908645,"median":-10.50763,"eighty":-7.57654,"marketCap":357369573},{"date":"2025-01-03","current":-6.374574,"twenty":-12.853892,"median":-10.405691,"eighty":-7.549864,"marketCap":339426951},{"date":"2025-01-10","current":-5.995231,"twenty":-12.800672,"median":-10.212067,"eighty":-7.505069,"marketCap":319228040},{"date":"2025-01-17","current":-4.918377,"twenty":-12.651961,"median":-10.173232,"eighty":-7.427764,"marketCap":261888801},{"date":"2025-01-24","current":-4.346472,"twenty":-12.574112,"median":-10.030358,"eighty":-7.086806,"marketCap":231436615},{"date":"2025-01-31","current":-4.332524,"twenty":-12.537284,"median":-9.920586,"eighty":-6.842433,"marketCap":230693879},{"date":"2025-02-07","current":-6.50018,"twenty":-12.535901,"median":-9.842528,"eighty":-6.605719,"marketCap":346115092},{"date":"2025-02-14","current":-5.236411,"twenty":-12.52887,"median":-9.777894,"eighty":-6.491539,"marketCap":278823188},{"date":"2025-02-21","current":-4.829104,"twenty":-12.471907,"median":-9.750601,"eighty":-6.430271,"marketCap":257135289},{"date":"2025-02-28","current":-4.770518,"twenty":-12.349943,"median":-9.721942,"eighty":-6.303838,"marketCap":254015797},{"date":"2025-03-07","current":-4.672876,"twenty":-12.236804,"median":-9.661093,"eighty":-6.2189,"marketCap":248816643},{"date":"2025-03-14","current":-4.686825,"twenty":-12.214976,"median":-9.588204,"eighty":-6.130619,"marketCap":249559380},{"date":"2025-03-21","current":-4.24883,"twenty":-12.149292,"median":-9.555425,"eighty":-6.004158,"marketCap":226237461},{"date":"2025-03-28","current":-3.045755,"twenty":-12.12341,"median":-9.468113,"eighty":-5.45457,"marketCap":228870246},{"date":"2025-04-04","current":-1.92123,"twenty":-12.043093,"median":-9.418302,"eighty":-5.225252,"marketCap":144368903},{"date":"2025-04-11","current":-1.782154,"twenty":-12.004592,"median":-9.374415,"eighty":-5.034123,"marketCap":133918207},{"date":"2025-04-17","current":-2.044108,"twenty":-11.997937,"median":-9.328916,"eighty":-4.961897,"marketCap":153602450},{"date":"2025-04-25","current":-2.917172,"twenty":-11.976697,"median":-9.167755,"eighty":-4.922368,"marketCap":219207954},{"date":"2025-05-02","current":-2.922866,"twenty":-11.956745,"median":-9.074937,"eighty":-4.83359,"marketCap":219635816}],"updateTime":1746270031365}}}